PTCT Key Statistics, Chart & Performance
The current stock price of PTCT is 75.56 USD. In the past month the price decreased by -2.04%. In the past year, price increased by 57.31%.
PTCT Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to PTCT. When comparing the yearly performance of all stocks, PTCT is one of the better performing stocks in the market, outperforming 90.12% of all stocks.
PTCT Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PTCT. Both the profitability and the financial health of PTCT get a neutral evaluation. Nothing too spectacular is happening here.
PTCT Financial Highlights
Over the last trailing twelve months PTCT reported a non-GAAP Earnings per Share(EPS) of 7.26. The EPS increased by 277.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 42.25% | ||
| ROA | 28.43% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PTCT Forecast & Estimates
22 analysts have analysed PTCT and the average price target is 83.91 USD. This implies a price increase of 11.05% is expected in the next year compared to the current price of 75.56.
For the next year, analysts expect an EPS growth of 263.62% and a revenue growth 123.95% for PTCT
PTCT Ownership
PTCT Latest News, Press Relases and Analysis
PTCT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.87 | 382.02B | ||
| AMGN | AMGEN INC | 15.71 | 185.02B | ||
| GILD | GILEAD SCIENCES INC | 15.76 | 160.18B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.56 | 117.00B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.65 | 78.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 716.59 | 48.28B | ||
| INSM | INSMED INC | N/A | 33.34B | ||
| NTRA | NATERA INC | N/A | 33.51B | ||
| BIIB | BIOGEN INC | 10.31 | 25.32B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.72B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.8 | 20.23B | ||
| INCY | INCYTE CORP | 16.3 | 20.55B |
Related stock screener links
About PTCT
Company Profile
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company is headquartered in Warren, New Jersey and currently employs 939 full-time employees. The company went IPO on 2013-06-20. The firm is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Company Info
PTC THERAPEUTICS INC
500 Warren Corporate Center Drive
WARREN NEW JERSEY 07080 US
CEO: Stuart W. Peltz
Employees: 939
Phone: 19082227000
PTC THERAPEUTICS INC / PTCT FAQ
What does PTC THERAPEUTICS INC do?
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company is headquartered in Warren, New Jersey and currently employs 939 full-time employees. The company went IPO on 2013-06-20. The firm is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
What is the current price of PTCT stock?
The current stock price of PTCT is 75.56 USD. The price increased by 3.41% in the last trading session.
What is the dividend status of PTC THERAPEUTICS INC?
PTCT does not pay a dividend.
What is the ChartMill rating of PTC THERAPEUTICS INC stock?
PTCT has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about PTC THERAPEUTICS INC (PTCT) stock?
22 analysts have analysed PTCT and the average price target is 83.91 USD. This implies a price increase of 11.05% is expected in the next year compared to the current price of 75.56.
Can you provide the number of employees for PTC THERAPEUTICS INC?
PTC THERAPEUTICS INC (PTCT) currently has 939 employees.
Can you provide the ownership details for PTCT stock?
You can find the ownership structure of PTC THERAPEUTICS INC (PTCT) on the Ownership tab.